Core Viewpoint - Organon reported quarterly earnings of $0.87 per share, exceeding the Zacks Consensus Estimate of $0.85 per share, with a year-over-year comparison showing no change in earnings [1] - The company achieved revenues of $1.58 billion for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 1.37% and showing an increase from $1.52 billion a year ago [2] Group 1: Earnings Performance - Organon has surpassed consensus EPS estimates in all four of the last quarters, indicating consistent performance [2] - The recent quarterly report represents an earnings surprise of 2.35%, following a previous surprise of 5.66% when actual earnings were $1.12 compared to an expected $1.06 [1][2] Group 2: Revenue Insights - The company has topped consensus revenue estimates three times over the last four quarters, demonstrating strong revenue growth [2] - The current consensus EPS estimate for the upcoming quarter is $1 on revenues of $1.56 billion, while the estimate for the current fiscal year is $4.22 on revenues of $6.35 billion [7] Group 3: Stock Performance and Outlook - Organon shares have increased by approximately 24.3% since the beginning of the year, outperforming the S&P 500's gain of 21.9% [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it is expected to perform in line with the market in the near future [6] Group 4: Industry Context - The Medical Services industry, to which Organon belongs, is currently ranked in the bottom 35% of over 250 Zacks industries, which may impact stock performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Core Viewpoint - Organon's upcoming quarterly earnings report is anticipated to show a slight decline in earnings per share but a modest increase in revenue compared to the previous year [1] Financial Performance - Expected quarterly earnings of $0.85 per share, a decrease of 2.3% year-over-year [1] - Forecasted revenues of $1.56 billion, reflecting a year-over-year increase of 2.7% [1] - Analysts have revised the consensus EPS estimate upward by 1.1% over the past 30 days [1] Revenue Estimates by Segment - Revenue from Women's Health - Nexplanon/Implanon NXT is estimated at $238.19 million, indicating an 8.3% increase year-over-year [3] - Revenue from Women's Health - Follistim AQ is projected at $66.32 million, showing a 22.8% increase from the prior year [4] - Total revenue from Biosimilars is expected to reach $168.58 million, reflecting an 18.7% increase year-over-year [4] - Total revenue from Women's Health is estimated at $452.30 million, indicating an 8.2% increase from the previous year [5] - Revenue from Women's Health - U.S. - Nexplanon/Implanon NXT is projected at $164.46 million, a 12.6% increase year-over-year [5] - Geographic revenue from the U.S. is expected to be $400.64 million, reflecting an 8.3% increase from the prior year [6] - Revenue from Women's Health - U.S. - NuvaRing is expected to decline to $10.08 million, a decrease of 44% year-over-year [6] - Revenue from Women's Health - U.S. - Follistim AQ is projected at $25.52 million, indicating a 16% increase from the previous year [7] - Revenue from Established Brands - Int'l - Non-Opioid Pain, Bone and Dermatology - Other is expected to be $69.71 million, a slight decrease of 0.4% year-over-year [8] - Revenue from Established Brands - Int'l - Non-Opioid Pain, Bone and Dermatology - Diprospan is projected at $34.34 million, reflecting a 10.8% increase [8] - Revenue from Established Brands - Int'l - Non-Opioid Pain, Bone and Dermatology - Fosamax is expected to be $35.27 million, a decrease of 11.8% year-over-year [9] Stock Performance - Over the past month, Organon's shares have declined by 10.5%, while the Zacks S&P 500 composite has increased by 2% [9] - Organon currently holds a Zacks Rank 3 (Hold), suggesting its performance may align with the overall market in the near future [9]

Core Viewpoint - Organon (OGN) is anticipated to report a year-over-year decline in earnings despite an increase in revenues for the quarter ending September 2024, with the earnings report set to be released on October 31, 2024 [1] Financial Expectations - The consensus estimate for Organon's quarterly earnings is $0.85 per share, reflecting a year-over-year decrease of 2.3% [2] - Expected revenues for the quarter are $1.56 billion, which represents a 2.7% increase from the same quarter last year [2] Estimate Revisions - Over the last 30 days, the consensus EPS estimate has been revised 1.06% higher, indicating a reassessment by covering analysts [3] - The Most Accurate Estimate for Organon is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -3.76%, suggesting a bearish outlook from analysts [6] Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a favorable Zacks Rank [5] - Organon currently holds a Zacks Rank of 3, making it challenging to predict an earnings beat conclusively [6] Historical Performance - In the last reported quarter, Organon exceeded the expected earnings of $1.06 per share by delivering $1.12, resulting in a surprise of +5.66% [7] - Over the past four quarters, Organon has beaten consensus EPS estimates three times [7] Conclusion - An earnings beat or miss may not solely dictate stock movement, as other factors can influence investor sentiment [8] - Organon does not appear to be a compelling candidate for an earnings beat, and investors should consider additional factors before making investment decisions [8]

Group 1: Company Performance - Organon closed at $18.10, with a +0.56% change from the previous day, lagging behind the S&P 500's gain of 0.77% [1] - The stock has decreased by 12.07% over the past month, underperforming the Medical sector's loss of 3% and the S&P 500's gain of 4.87% [1] Group 2: Upcoming Earnings - Organon's earnings report is expected on October 31, 2024, with projected earnings of $0.97 per share, indicating a year-over-year growth of 11.49% [2] - The Zacks Consensus Estimate for revenue is $1.56 billion, reflecting a 2.44% increase from the previous year [2] Group 3: Fiscal Year Estimates - For the entire fiscal year, earnings are estimated at $4.34 per share and revenue at $6.34 billion, showing changes of +4.83% and +1.28% respectively from the prior year [3] Group 4: Analyst Estimates - Recent changes to analyst estimates for Organon are important as they reflect short-term business trends and analysts' confidence in the company's performance [4] - The Zacks Rank system, which considers these estimate changes, provides an operational rating system for investors [5] Group 5: Zacks Rank and Valuation - Organon currently holds a Zacks Rank of 3 (Hold), with the Zacks Consensus EPS estimate having increased by 0.3% in the past month [6] - The company has a Forward P/E ratio of 4.14, significantly lower than the industry average of 20.29, and a PEG ratio of 0.75 compared to the industry average of 1.81 [7] Group 6: Industry Context - The Medical Services industry, which includes Organon, has a Zacks Industry Rank of 192, placing it in the bottom 24% of over 250 industries [8] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [8]

Organon (OGN) has been on a downward spiral lately with significant selling pressure. After declining 9.9% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier. Guide to Identifying Oversold Stocks We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is o ...

In the latest market close, Organon (OGN) reached $18.58, with a -1.33% movement compared to the previous day. This change lagged the S&P 500's 0.01% gain on the day. Elsewhere, the Dow saw an upswing of 0.09%, while the tech-heavy Nasdaq appreciated by 0.08%. Prior to today's trading, shares of the pharmaceutical company had lost 14.72% over the past month. This has lagged the Medical sector's loss of 3.6% and the S&P 500's gain of 1.21% in that time. Analysts and investors alike will be keeping a close ey ...

In the latest market close, Organon (OGN) reached $19.17, with a +0.74% movement compared to the previous day. The stock exceeded the S&P 500, which registered a gain of 0.4% for the day. On the other hand, the Dow registered a gain of 0.62%, and the technology-centric Nasdaq increased by 0.6%. The pharmaceutical company's stock has dropped by 15.31% in the past month, falling short of the Medical sector's loss of 2.27% and the S&P 500's gain of 1.71%. The investment community will be closely monitoring the ...

Company Performance - Organon (OGN) closed at $20.47, with a daily gain of +0.89%, outperforming the S&P 500's gain of 0.54% [1] - Over the past month, Organon's shares increased by 0.35%, lagging behind the Medical sector's gain of 4.37% and the S&P 500's gain of 4.86% [1] Upcoming Earnings - The upcoming earnings release is anticipated, with a forecasted EPS of $0.97, reflecting an 11.49% increase from the same quarter last year [2] - Revenue is projected at $1.56 billion, indicating a 2.44% rise from the equivalent quarter last year [2] Annual Estimates - For the annual period, earnings are expected to be $4.33 per share, with revenue anticipated at $6.34 billion, representing increases of +4.59% and +1.28% respectively from the previous year [3] Analyst Projections - Recent shifts in analyst projections should be monitored, as positive revisions indicate optimism regarding the company's business and profitability [4] Zacks Rank and Valuation - Organon currently holds a Zacks Rank of 4 (Sell), with the consensus EPS estimate remaining unchanged over the last 30 days [6] - The Forward P/E ratio for Organon is 4.68, significantly lower than the industry average of 22.16, and the PEG ratio stands at 0.85 compared to the industry average of 1.57 [7] Industry Context - The Medical Services industry, to which Organon belongs, has a Zacks Industry Rank of 173, placing it in the bottom 32% of over 250 industries [8]

Organon (OGN) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Over the past month, shares of this pharmaceutical company have returned +1%, compared to the Zacks S&P 500 composite's +4% change. During this period, the Zacks Medical Services industry, which Organon falls in, has gained 1.2%. The key question now is: What could be the stock's future direction? Altho ...

Organon (OGN) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Shares of this pharmaceutical company have returned +0.6% over the past month versus the Zacks S&P 500 composite's +3.2% change. The Zacks Medical Services industry, to which Organon belongs, has gained 2.5% over this period. Now the key question is: Where could the stock be headed in the near term? Alt ...